CSF3R and atypical chronic myeloid leukemia, BCR-ABL1 negative: The identification of mutations of the colony-stimulating factor 3 (CSF3R) in aCML has prompted the consideration of ruxolitinib to halt the aberrant signaling through JAK inhibition [69].